Recent developments in prebiotics to selectively impact beneficial microbes and promote intestinal health

Current Opinion in Biotechnology

Volumn 32, Issue , 2015, Pages 42-46

  Rastall, Robert A ^a   Gibson, Glenn R ^a  

^a UNIVERSITY OF READING   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOCHEMISTRY; HEALTH; LIPIDS; POLYSACCHARIDES;

BIFIDOBACTERIA; FEEDING STUDIES; FOOD INGREDIENTS; IMMUNE STIMULATION; INSULIN RESISTANCE; INTESTINAL HEALTHS; METABOLIC SYNDROMES; STIMULATORY EFFECTS;

BACTERIA;

BACTERIUM LIPOPOLYSACCHARIDE; C REACTIVE PROTEIN; FRUCTOSE OLIGOSACCHARIDE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INULIN; MALTODEXTRIN; MANNAN; OLIGOSACCHARIDE; PREBIOTIC AGENT; SHORT CHAIN FATTY ACID; UNCLASSIFIED DRUG; XYLOOLIGOSACCHARIDE; MINERAL;

ANTIINFLAMMATORY ACTIVITY; BIFIDOBACTERIUM; BIFIDOBACTERIUM ANIMALIS; BIOMASS PRODUCTION; BODY MASS; CALORIC INTAKE; CLOSTRIDIUM HISTOLYTICUM; DIET SUPPLEMENTATION; ENTEROBACTERIACEAE; FAECALIBACTERIUM PRAUSNITZII; HEALTH; HUMAN; INFLAMMATION; INTESTINAL HEALTH; MEDICAL RESEARCH; METABOLIC SYNDROME X; METHANOBREVIBACTER; MICROBIOLOGY; NONHUMAN; REVIEW; SATIETY; WEIGHT REDUCTION; WHEAT BRAN; ANIMAL; CARBOHYDRATE METABOLISM; INTESTINE; METABOLISM; OBESITY;

ANIMALS; CARBOHYDRATE METABOLISM; HUMANS; INFLAMMATION; INTESTINES; MINERALS; OBESITY; PREBIOTICS;

EID: 84911468165     PISSN: 09581669     EISSN: 18790429     Source Type: Journal    
DOI: 10.1016/j.copbio.2014.11.002     Document Type: Review

References (50)

1. Gibson G.R., Roberfroid M.B. Dietary modulation of the human colonic microbiota: introducing the concept of prebiotics. J Nutr 2005, 125:1401-1412.
2. Gibson G.R., Scott K.P., Rastall R.A., Tuohy K.M., Hotchkiss A., Dubert-Ferrandon A., Gareau M., Murphy E.F., Saulnier D., Loh G., Macfarlane S., Delzenne N., Ringel Y., Kozianowski G., Dickmann R., Lenoir-Wijnkook I., Walker C., Buddington R. Dietary prebiotics: current status and new definition. IFIS Funct Foods Bull 2010, 7:1-19.
3. Nicholson J.K., Holmes E., Kinross J., Burcelin R., Gibson G.R., Jia W., Pettersson S. Host-gut microbiota metabolic interactions. Science 2012, 336:1262-1267.
4. Holmes E., Kinross J., Gibson G.R., Burcelin R., Jia W., Pettersson S., Nicholson J.K. Therapeutic modulation of microbiota-host metabolic interactions. Sci Trans Med 2012, 4:137rv6.
5. Sanders M.E., Lenoir-Wijnkoop I., Salminen S., Merenstein D.J., Gibson G.R., Petschow B.W., Nieuwdorp M., Tancredi D.J., Cifelli C.J., Jacques P., Pot B. Probiotics and prebiotics: prospects for public health and nutritional recommendations. Ann NY Acad Sci 2014, 1309:19-29.
6. Brownawell A.M., Caers W., Gibson G.R., Kendall C.W., Lewis K.D., Ringel Y., Slavin J.L. Prebiotics and the health benefits of fiber: current regulatory status, future research, and goals. J Nutr 2012, 142:962-974.
7. Lewis S., Burmeister S., Brazier J. Effect of the prebiotic oligofructose on relapse of Clostridium difficile-associated diarrhea: a randomized, controlled study. Clin Gastroenterol Hepatol 2005, 3:442-448.
8. Whisner C.M., Martin B.R., Schoterman M.H., Nakatsu C.H., McCabe L.D., McCabe G.P., Wastney M.E., van den Heuvel E.G., Weaver C.M. Galactooligosaccharides increase calcium absorption and gut bifidobacteria in young girls: a double-blind cross-over trial. Br J Nutr 2013, 110:1-12.
9. Cummings J.H., Christie S., Cole T.J. A study of fructo oligosaccharides in the prevention of travellers' diarrhoea. Aliment Pharmacol Ther 2001, 15:1139-1145.
10. Drakoularakou A., Tzortzis G., Rastall R.A., Gibson G.R. A double-blind, placebo-controlled, randomized human study assessing the capacity of a novel galacto-oligosaccharide mixture in reducing travellers' diarrhoea. Eur J Clin Nutr 2010, 64:146-152.
11. Osborn D.A., Sinn J.K. Prebiotics in infants for prevention of allergy. Cochrane Database Syst Rev 2013, 3:CD006474.
12. Lomax A.R., Calder P.C. Prebiotics, immune function, infection and inflammation: a review of the evidence. Br J Nutr 2009, 101:633-658.
13. Silk D.B., Davis A., Vulevic J., Tzortzis G., Gibson G.R. Clinical trial: the effects of a trans-galactooligosaccharide prebiotic on faecal microbiota and symptoms in irritable bowel syndrome. Aliment Pharmacol Ther 2009, 29:508-518.
14. Whelan K. Probiotics and prebiotics in the management of irritable bowel syndrome: a review of recent clinical trials and systematic reviews. Curr Opin Clin Nutr Metab Care 2011, 14:581-587.
15. Leenen C.H., Dieleman L.C. Inulin and oligofructose in chronic inflammatory bowel disease. J Nutr 2007, 137:2572S-2575S.
16. Rastall R.A. Functional oligosaccharides: application and manufacture. Ann Rev Food Sci Technol 2010, 1:305-339.
17. Turnbaugh P.J., Bäckhed F., Fulton L., Gordon J.I. Diet-induced obesity is linked to marked but reversible alterations in the mouse distal gut microbiome. Cell Host Microbe 2008, 3:213-223.
18. Angelakis E., Armougom F., Million M., Raoult D. The relationship between gut microbiota and weight gain in humans. Fut Microbiol 2012, 7:91-109.
19. Fernandes J., Su W., Rahat-Rozenbloom S., Wolever T.M., Comelli E.M. Adiposity, gut microbiota and faecal short chain fatty acids are linked in adult humans. Nutr Diabetes 2014, 10.1038/nutd.2014.23.
20. Vulevic J., Juric A., Tzortzis G., Gibson G.R. A mixture of trans-galactooligosaccharides reduces markers of metabolic syndrome and modulates the fecal microbiota and immune function of overweight adults. J Nutr 2013, 143:324-331.
21. Fava F., Gitau R., Griffin B.A., Gibson G.R., Tuohy K.M., Lovegrove J.A. The type and quantity of dietary fat and carbohydrate alter faecal microbiome and short-chain fatty acid excretion in a metabolic syndrome 'at-risk' population. Int J Obesity 2012, 37:216-223. 10.1038/ijo.2012.33.
22. Salazar N., Dewulf E.M., Neyrinck A.M., Bindels L.B., Cani P.D., Mahillon J., de Vos W.M., Thissen J.P., Gueimonde M., de Los Reyes-Gavilán C.G., Delzenne N.M. Inulin-type fructans modulate intestinal Bifidobacterium species populations and decrease fecal short-chain fatty acids in obese women. Clin Nutr 2014, pii:S0261-5614(14)00159-9. 10.1016/j.
23. Dewulf E.M., Cani P.D., Claus P.D., Fuentes S., Puylaert P.G.B., Neyrinck A.M., Bindels L.B., de Vos W.M., Gibson G.R., Thissen J.P., Delzenne N.M. Insight into the prebiotic concept: lessons from an exploratory, double blind intervention study with inulin-type fructans in obese women. Gut 2012, 62:1112-1121.
24. Verhoef S.P.M., Meyer D., Westerterp K.R. Effects of oligofructose on appetite profile, glucagon-like peptide 1 and peptide YY3-36 concentrations and energy intake. Br J Nutr 2011, 106:1757-1762.
25. Frost G., Sleeth M.L., Sahuri-Arisoylu M., Lizarbe B., Cerdan S., Brody L., Anastasovska J., Ghourab S., Hankir M., Zhang S., Carling D., Swann J.R., Gibson G.R., Viardot A., Morrison D., Thomas L.E., Bell J.D. The short-chain fatty acid acetate reduces appetite via a central homeostatic mechanism. Nat Commun 2014, 5:3611. 10.1038/ncomms4611.
26. Liber A., Szajewska H. Effects of inulin-type fructans on appetite, energy intake, and body weight in children and adults: systematic review of randomized controlled trials. Ann Nutr Metab 2013, 63:42-54.
27. Cani P.D., Lecourt E., Dewulf E.M., Sohet F.M., Pachikian B.D., Naslain D., De Backer F., Neyrinck A.M., Delzenne N.M. Gut microbiota fermentation of prebiotics increases satietogenic and incretin gut peptide production with consequences for appetite sensation and glucose response after a meal. Am J Clin Nutr 2009, 90:1236-1243.
28. Cani P.D., Joly E., Horsmans Y., et al. Oligofructose promotes satiety in healthy human: a pilot study. Eur J Clin Nutr 2006, 60:567-572.
29. Parnell J.A., Reimer R.A. Weight loss during oligofructose supplementation is associated with decreased ghrelin and increased peptide YY in overweight and obese adults. Am J Clin Nutr 2009, 89:1751-1759.
30. Delzenne N.M., Neyrinck A.M., Cani P.D. Gut microbiota and metabolic disorders: how prebiotic can work?. Br J Nutr 2013, 109:S81-S85.
31. Russo F., Linsalata M., Clemente C., Chiloiro M., Orlando A., Marconi E., Chimienti G., Riezzo G. Inulin-enriched pasta improves intestinal permeability and modifies the circulating levels of zonulin and glucagon-like peptide 2 in healthy young volunteers. Nutr Res 2012, 32:940-946.
32. Dehghan P., Gargari B.P., Jafar-abadi M.A. Oligofructose-enriched inulin improves some inflammatory markers and metabolic endotoxemia in women with type 2 diabetes mellitus: a randomized controlled clinical trial. Nutrition 2013, 30:418-423.
33. Sarbini S.R., Rastall R.A. Prebiotics: metabolism, structure, and function. Funct Food Rev 2011, 3:93-106.
34. Depeint F., Tzortzis G., Vulevic J., I'anson K., Gibson G.R. Prebiotic evaluation of a novel galactooligosaccharide mixture produced by the enzymatic activity of Bifidobacterium bifidum NCIMB 41171, in healthy humans: a randomized, double-blind, crossover, placebo-controlled intervention study. Am J Clin Nutr 2008, 87:785-791.
35. Walton G.E., van den Heuvel E.G., Kosters M.H., Rastall R.A., Tuohy K.M., Gibson G.R. A randomised crossover study investigating the effects of galacto-oligosaccharides on the faecal microbiota in men and women over 50 years of age. Br J Nutr 2012, 107:1466-1475.
36. Dais L.M.G., Martinez I., Walter J., Goin C., Hutkins R.W. Barcoded pyrosequencing reveals that consumption of galactooligosaccharides results in a highly specific bifidogenic response in humans. PLoS ONE 2011, 6:e25200.
37. Cardelle-Cobas A., Agustín Olano A., Corzo N., Villamiel M., Collins M., Kolida S., Rastall R.A. In vitro fermentation of lactulose-derived oligosaccharides by mixed fecal microbiota. J Agric Food Chem 2012, 60:2024-2032.
38. Sarbini S.R., Kolida S., Gibson G.R., Rastall R.A. In vitro fermentation of commercial α-gluco-oligosaccharide by faecal microbiota from lean and obese human subjects. Br J Nutr 2013, 109:1980-1989.
39. Martín R., Chain F., Miquel S., Lu J., Gratadoux J.J., Sokol H., Verdu E.F., Bercik P., Bermúdez-Humarán L.G., Langella P. The commensal bacterium Faecalibacterium prausnitzii is protective in DNBS-induced chronic moderate and severe colitis models. Inflamm Bowel Dis 2014, 20:417-443.
40. Gullon P., Gullon B., Moure A., Alonso J.L., Dominiguez H., Parajo J.C. Manufacture of prebiotics from biomass sources. Prebiotics and Probiotics Science and Technology 2013, 535-589. Springer. D. Charalampopoulos, R.A. Rastall (Eds.).
41. Ho A.L., Carvalheiro F., Duarte L.C., Roseiro L.B., Charalampopoulos D., Rastall R.A. Production and purification of xylooligosaccharides from oil palm empty fruit bunch fibre by a non-isothermal process. Bioresour Technol 2014, 152:526-529.
42. Rivas S., Gullón B., Gullón P., Alonso J.L., Parajó J.C. Manufacture and properties of bifidogenic saccharides derived from wood mannan. J Agric Food Chem 2012, 60:4296-4305.
43. Finegold S.M., Li Z., Summanen P.H., Downes J., Thames G., Corbett K., Dowd S., Krak M., Heberd D. Xylooligosaccharide increases bifidobacteria but not lactobacilli in human gut microbiota. Food Funct 2014, 5:445.
44. Sim K., Cox M.J., Wopereis H., Martin R., Knol J., Li M.S., Cookson W.O., Moffatt M.F., Kroll J.S. Improved detection of bifidobacteria with optimised 16S rRNA-gene based pyrosequencing. PLoS ONE 2012, 7:e32543.
45. Childs C.E., Roytio H., Alhoniemi E., Fekete A.A., Forssten S.D., Hudjec N., Lim Y.N., Steger C.J., Yaqoob P., Tuohy K.M., Rastall R.A., Ouwehand A.C., Gibson G.R. Xylo-oligosaccharides alone or in synbiotic combination with Bifidobacterium animalis subsp. lactis induce bifidogenesis and modulate markers of immune function in healthy adults: a double-blind, placebo-controlled, randomised, factorial cross-over study. Br J Nutr 2014, 111:1945-1956.
46. François I.E., Lescroart O., Veraverbeke W.S., Marzorati M., Possemiers S., Evenepoel P., Hamer H., Houben E., Windey K., Welling G.W., Delcour J.A., Courtin C.M., Verbeke K., Broekaert W.F. Effects of a wheat bran extract containing arabinoxylan oligosaccharides on gastrointestinal health parameters in healthy adult human volunteers: a double-blind, randomised, placebo-controlled, cross-over trial. Br J Nutr 2012, 108:2229-2242.
47. Maki K.C., Gibson G.R., Dickmann R.S., Kendall C.W., Chen C.Y., Costabile A., Comelli E.M., McKay D.L., Almeida N.G., Jenkins D., Zello G.A., Blumberg J.B. Digestive and physiologic effects of a wheat bran extract, arabino-xylan-oligosaccharide, in breakfast cereal. Nutrition 2012, 28:1115-1121.
48. Walton G.E., Lu C., Trogh I., Arnaut F., Gibson G.R. A randomised, double-blind, placebo controlled cross-over study to determine the gastrointestinal effects of consumption of arabinoxylanoligosaccharides enriched bread in healthy volunteers. Nutr J 2012, 11:36-46.
49. Lecerf J.M., Depeint F., Clerc E., Dugenet Y., Niamba C.N., Rhazi L., Cayzeele A., Abdelnour G., Jaruga A., Younes H., Jacobs H., Lambrey G., Abdelnour A.M., Pouillart P.R. Xylo-oligosaccharide (XOS) in combination with inulin modulates both the intestinal environment and immune status in healthy subjects, while XOS alone only shows prebiotic properties. Br J Nutr 2012, 108:1847-1858.
50. Roberfroid M., Gibson G.R., Hoyles L., McCartney A.L., Rastall R., Rowland I., Wolvers D., Watzl B., Szajewska H., Stahl B., Guarner F., Respondek F., Whelan K., Coxam V., Davicco M., Léotoing L., Wittrant Y., Delzenne N., Cani P., Neyrinck A., Meheust A. Prebiotic effects: metabolic and health benefits. Br J Nutr 2010, 104:S1-S63.